Cardiff Oncology 관리

관리 기준 확인 3/4

Cardiff Oncology CEO는 Mark Erlander, May2020 에 임명되었습니다 의 임기는 4.5 년입니다. 총 연간 보상은 $ 1.55M, 38.4% 로 구성됩니다. 38.4% 급여 및 61.6% 보너스(회사 주식 및 옵션 포함). 는 € 58.92K 가치에 해당하는 회사 주식의 0.048% 직접 소유합니다. 58.92K. 경영진과 이사회의 평균 재임 기간은 각각 2.8 년과 10.2 년입니다.

주요 정보

Mark Erlander

최고 경영자

US$1.5m

총 보상

CEO 급여 비율	38.4%
CEO 임기	4.5yrs
CEO 소유권	0.05%
경영진 평균 재임 기간	2.8yrs
이사회 평균 재임 기간	10.2yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Mark Erlander 의 보수는 Cardiff Oncology 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$43m
Jun 30 2024	n/a	n/a	-US$41m
Mar 31 2024	n/a	n/a	-US$40m
Dec 31 2023	US$2m	US$594k	-US$41m
Sep 30 2023	n/a	n/a	-US$41m
Jun 30 2023	n/a	n/a	-US$40m
Mar 31 2023	n/a	n/a	-US$39m
Dec 31 2022	US$2m	US$571k	-US$39m
Sep 30 2022	n/a	n/a	-US$39m
Jun 30 2022	n/a	n/a	-US$38m
Mar 31 2022	n/a	n/a	-US$34m
Dec 31 2021	US$4m	US$533k	-US$28m
Sep 30 2021	n/a	n/a	-US$25m
Jun 30 2021	n/a	n/a	-US$23m
Mar 31 2021	n/a	n/a	-US$24m
Dec 31 2020	US$1m	US$445k	-US$23m
Sep 30 2020	n/a	n/a	-US$20m
Jun 30 2020	n/a	n/a	-US$20m
Mar 31 2020	n/a	n/a	-US$17m
Dec 31 2019	US$853k	US$399k	-US$17m
Sep 30 2019	n/a	n/a	-US$17m
Jun 30 2019	n/a	n/a	-US$16m
Mar 31 2019	n/a	n/a	-US$19m
Dec 31 2018	US$909k	US$387k	-US$19m
Sep 30 2018	n/a	n/a	-US$18m
Jun 30 2018	n/a	n/a	-US$18m
Mar 31 2018	n/a	n/a	-US$20m
Dec 31 2017	US$1m	US$374k	-US$25m

보상 대 시장: Mark 의 총 보상 ($USD 1.55M )은 German 시장( $USD 475.63K ).

보상과 수익: Mark 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Mark Erlander (64 yo)

4.5yrs

테뉴어

US$1,547,772

보상

Dr. Mark Erlander, Ph D., is Chief Executive Officer of Cardiff Oncology, Inc. (formerly known as TrovaGene, Inc.) since May 2020 and was its Chief Scientific Officer March 4, 2013 to April 2020. Dr. Erlan...

리더십 팀

이름	위치	테뉴어	보상	소유권
Mark Erlander	CEO & Director	4.5yrs	US$1.55m	0.048% € 58.9k
James Levine	Chief Financial Officer	3.3yrs	US$917.72k	0.12% € 144.4k
Fairooz Kabbinavar	Chief Medical Officer	1.8yrs	US$1.26m	0% € 0
Tod Smeal	Chief Scientific Officer	2.8yrs	US$4.17m	0% € 0
Elizabeth Anderson	VP of Finance & Administration	9.3yrs	데이터 없음	데이터 없음
Brigitte Lindsay	Senior Vice President of Finance	1.8yrs	데이터 없음	데이터 없음
Charles Monahan	Senior Vice President of Regulatory Affairs	2.8yrs	데이터 없음	데이터 없음

2.8yrs

평균 재임 기간

61.5yo

평균 연령

경험이 풍부한 관리: XE7C 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Mark Erlander	CEO & Director	4.4yrs	US$1.55m	0.048% € 58.9k
Charles Cantor	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Gary Pace	Independent Director	4.6yrs	US$114.43k	1.36% € 1.7m
K. Hirth	Member of Scientific Advisory Board	10.3yrs	데이터 없음	데이터 없음
Paul Billings	Member of Scientific Advisory Board	12yrs	US$35.85k	데이터 없음
Rodney Markin	Independent Chairman of the Board	10.8yrs	US$154.43k	0.061% € 74.7k
Carlo Croce	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Riccardo Dalla-Favera	Member of Scientific Advisory Board	14.6yrs	데이터 없음	데이터 없음
Lale White	Independent Director	4.6yrs	US$116.43k	0.22% € 273.8k
Alberto Bardelli	Member of Scientific Advisory Board	10.2yrs	데이터 없음	데이터 없음
Renee Tannenbaum	Independent Director	3.4yrs	US$110.43k	0.020% € 24.1k
Brunangelo Falini	Member of Scientific Advisory Board	14.6yrs	데이터 없음	데이터 없음

10.2yrs

평균 재임 기간

72yo

평균 연령

경험이 풍부한 이사회: XE7C 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.2 년).

Cardiff Oncology 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Insufficient new directors

Cardiff Oncology, Inc., Annual General Meeting, Jun 20, 2024

Cardiff Oncology Appoints Fairooz Kabbinavar as Chief Medical Officer

Independent Director recently bought €257k worth of stock

Cardiff Oncology, Inc., Annual General Meeting, Jun 09, 2022

Cardiff Oncology, Inc. Announces Executive Changes

Recent updates

Third quarter 2024 earnings released: US$0.25 loss per share (vs US$0.22 loss in 3Q 2023)

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$0.26 loss per share (vs US$0.25 loss in 2Q 2023)

Cardiff Oncology, Inc. to Report Q2, 2024 Results on Aug 08, 2024

New major risk - Financial position

Insufficient new directors

First quarter 2024 earnings released: US$0.22 loss per share (vs US$0.25 loss in 1Q 2023)

Cardiff Oncology, Inc., Annual General Meeting, Jun 20, 2024

Cardiff Oncology Presents Novel Preclinical Data At Aacr Annual Meeting 2024 That Supports Ongoing First-Line Ras-Mutated Mcrc Clinical Study

Full year 2023 earnings released: US$0.93 loss per share (vs US$0.89 loss in FY 2022)

Cardiff Oncology, Inc. Announces First Patient Dosed in Randomized First-Line RAS-Mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Cardiff Oncology, Inc. Provides Clinical Update on Phase 2 Randomized Second-Line ONSEMBLE Trial in Patients with RAS-Mutated mCRC

Cardiff Oncology, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Third quarter 2023 earnings released: US$0.22 loss per share (vs US$0.20 loss in 3Q 2022)

Cardiff Oncology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Cardiff Oncology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Cardiff Oncology, Inc. Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, Including Single-Agent Activity from Onvansertib Monotherapy

Second quarter 2023 earnings released: US$0.25 loss per share (vs US$0.24 loss in 2Q 2022)

Cardiff Oncology, Inc Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship

First quarter 2023 earnings released: US$0.25 loss per share (vs US$0.25 loss in 1Q 2022)

Full year 2022 earnings released: US$0.89 loss per share (vs US$0.72 loss in FY 2021)

Cardiff Oncology Appoints Fairooz Kabbinavar as Chief Medical Officer

Third quarter 2022 earnings released: US$0.20 loss per share (vs US$0.17 loss in 3Q 2021)

Independent Director recently bought €257k worth of stock

Cardiff Oncology, Inc. Announces Plans for A Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1B/2 Trial in mCRC

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.17 loss in 2Q 2021)

Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from Russell 2000 Value Index

First quarter 2022 earnings released: EPS: US$0 (vs US$0.14 loss in 1Q 2021)

Cardiff Oncology, Inc., Annual General Meeting, Jun 09, 2022

Cardiff Oncology, Inc. Announces Executive Changes

Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.19 loss in 3Q 2020)

Independent Director recently bought €173k worth of stock

Chief Financial Officer recently bought €164k worth of stock

Cardiff Oncology, Inc. Announces New Data from Phase 1B/2 Trial in KRAS-Mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$0.51 loss in 2Q 2020)

Independent Director Gary Jacob has left the company

Independent Director Thomas Adams has left the company

Cardiff Oncology, Inc. Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic Cancer

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.41 loss in 1Q 2020)

Independent Director recently bought €86k worth of stock

Full year 2020 earnings released: US$1.08 loss per share (vs US$2.80 loss in FY 2019)

Revenue beats expectations

New 90-day low: €8.05

Cardiff Oncology, Inc. Updates Data from Its Phase 2 Metastatic Castrate-Resistant Prostate Cancer Trial Were Featured in A Virtual Oral Poster Presentation At the American Society of Clinical Oncology Genitourinary Cancers Symposium

Cardiff Oncology Receives "Study May Proceed" from FDA to Initiate Phase 2 Trial of Onvansertib in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

New 90-day low: €10.10

Cardiff Oncology, Inc. Developing New Treatment Options for Cancer Patients in Indications with the Greatest Medical Need

Cardiff Oncology Presents Data That Continues to Demonstrate the Clinical Benefit of Onvansertib in KRAS-Mutated mCRC and Initial Findings from Its Expanded Access Program

Cardiff Oncology, Inc. Announces Executive Changes

Cardiff Oncology, Inc. Presents Data at ASH Demonstrating the Safety and Anti-Leukemic Activity of Onvansertib in Patients with Relapsed/Refractory AML

Third quarter 2020 earnings released: US$0.19 loss per share

Revenue beats expectations

New 90-day high: €14.00

New 90-day high: €13.60

Cardiff Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $87.75 million.

New 90-day high: €6.95

Cardiff Oncology, Inc. Presents Data At ESMO Confirming Efficacy of Onvansertib and Durability of Response in KRAS-Mutated Metastatic Colorectal Cancer

New 90-day high - €6.05

First half earnings released

New 90-day high - €4.54

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령